Latest News-CliniExpert

Bayer Starts Phase III Clinical Development Program OASIS With Investigational Product, Elinzanetant

Elinzanetant is a non-hormonal development compound investigated for the treatment of vasomotor symptoms during menopause WHIPPANY, N.J.--(BUSINESS WIRE) August 31, 2021-- Bayer, a global leader in wo

Novavax Statement on CDC Guidance Update for COVID-19 Clinical Trial Participants

GAITHERSBURG, Md., Aug. 30, 2021 -- Novavax, Inc. , a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that the U.S. Centers for Disease Contr

Positive Top-Line Results From Pfizer’s Phase 3 JADE DARE Trial Comparing the Efficacy of Abrocitinib and Dupilumab for Moderate to Severe Atopic Dermatitis

NEW YORK--(BUSINESS WIRE) August 30, 2021 -- Pfizer Inc. (NYSE: PFE) today announced that JADE DARE (B7451050), a 26-week, randomized, double-blind, double-dummy, active-controlled, multi-center Phase

Study Data Show Abbott's CardioMEMSDevice Can Improve Care for More Patients with Heart Failure

ABBOTT PARK, Ill., Aug. 27, 2021 -- Abbott today announced results of the landmark GUIDE-HF clinical trial, a 1,000 patient randomized study designed to assess the benefits of the CardioMEMS HF System

Airway Therapeutics Announces First Patient Dosed in Phase 1b Trial of AT-100 in Severe COVID-19 Patients

CINCINNATI, Aug. 26, 2021 -- Airway Therapeutics, Inc. (Airway), a biopharmaceutical company developing a new class of biologics to break the cycle of injury and inflammation for patients with respira

INOVIO Receives Authorization to Conduct Phase 3 Efficacy Trial of its COVID-19 DNA Vaccine Candidate

PLYMOUTH MEETING, Pa., Aug. 26, 2021 -- INOVIO, a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and

ALXN1840 FoCus Phase III Trial in Wilson Disease Met Primary Endpoint Demonstrating Improvement in Copper Mobilisation from Tissues

ALXN1840 demonstrated approximately three times greater copper mobilisation from tissues than standard-of-care treatments 26 August 2021 -- Positive high-level results from the FoCus Phase III trial i

CytoDyn’s Final mTNBC Report Indicates as Much as 980% Increase in 12-Month Overall Survival and Up to 660% in 12-Month Modified Progression Free Survival

VANCOUVER, Washington, Aug. 25, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab, a CCR5 a

Novavax to Participate in OCTAVE-DUO Study to Evaluate Third Dose of Vaccine in Participants with Impaired Immune Systems

GAITHERSBURG, Md., Aug. 25, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that Novavax

Oramed Reaches 25% Enrollment in Its Second of Two Concurrent Phase 3 Oral Insulin Trials

NEW YORK, Aug. 24, 2021 -- Oramed Pharmaceuticals Inc., a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, announced today that it has enrolled and ran

Theravance Biopharma, Inc. Announces Top-line Results from Phase 2b Dose-Finding Induction Study of Izencitinib in Patients with Ulcerative Colitis

DUBLIN and SOUTH SAN FRANCISCO, Calif., Aug. 23, 2021 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH), a diversified biopharmace

AZD7442 PROVENT Phase III Prophylaxis Trial Met Primary Endpoint in Preventing COVID-19

77% reduced risk of developing symptomatic COVID-19 First long-acting antibody combination to prevent COVID-19 20 August 2021 -- Positive high-level results from the PROVENT Phase III pre-exposure pro